Clinical Trial Update: Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of Ro 31-7453 for recurrent or refractory metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Ro 31-7453

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED